nutrition-health-gastroenterologists-2019-keynote

5 / 8

allied
academies
Page 16
Journal of Nutrition and Human Health | Volume 3
May 23-24, 2019 | Vienna, Austria
Joint Event
2nd International Conference on Gastroenterology and Digestive Disorders
17th International Conference on Nutrition and Fitness
&
The overall 5-year survival rate for pancreatic cancer
(8%) has changed little over the past few decades,
and this tumour is predicted to be the second leading
cause of cancer-related mortality in the next decade in
Western countries. During the past few years, however,
clinically relevant improvements in first-line and second-
line palliative therapies and significant progress in
increasing survival with adjuvant treatment have been
achived. The potential of neoadjuvant therapies also offers
opportunities to improve outcomes. This review will bring
together information on achievements to date, and where
successes are likely to be achieved in the future. The
questions of how we should approach the development
of pancreatic cancer treatments, including those for
patients with metastatic, locally advanced and borderline
resectable pancreatic cancer, as well as for patients with
resected tumours will be addressed.
Speaker Biography
ScheithauerW is a Professor of Internal Medicine at theMedical University
in Vienna, Austria. His main research interests include the preclinical and
clinical evaluation of new anticancer agents and biologics, especially in
gastrointestinal malignancies, on which he has published 273 original
papers in peer-reviewed journals, more than 60 book chapters, and over
600 abstracts.
e:
Scheithauer W
Medical University Vienna, Austria
Advances in the therapeutic management of Pancreatic Cancer -
Current and future perspectives
Notes: